A cooperative model may at time better serve the relationship between patient and clinician.

Lurbinectedin plus atezolizumab significantly reduced the risk of disease progression or death by 46% compared with atezolizumab alone.

Researchers reviewed cases in which patients experienced severe skin toxicities in response to immunotherapy, and sought to identify the distinct natures of these toxicities.

HealthDay News — From 1999 to 2020, obesity-related cancer mortality increased significantly, according to a study presented at ENDO 2025, the annual meeting of the Endocrine Society, held from July ...

The proportion of patients who receive a long-term opioid prescription following colorectal surgery has significantly decreased over time.

This study examined the posttreatment experiences of 7 children with brain tumor to determine whether problems with cognition, body function, and social functioning improved over time.

Sacituzumab tirumotecan showed “promising efficacy” regardless of PD-L1 status, said study presenter Yongmei Yin, MD, PhD.

To our knowledge, this is the first study that demonstrates a clinical advantage of proton therapy for NGGCT,” said David Y. Mak, MD.

Researchers sought to determine whether SOC pola-R-CHP frontline therapy would be safe and effective in a real-world population of patients with treatment-naïve DLBCL.